LLY

1,070.24

-1.32%↓

JNJ

223.71

+0.13%↑

ABBV

214.91

+0.85%↑

UNH

376.87

-0.39%↓

MRK

116.26

+0.55%↑

LLY

1,070.24

-1.32%↓

JNJ

223.71

+0.13%↑

ABBV

214.91

+0.85%↑

UNH

376.87

-0.39%↓

MRK

116.26

+0.55%↑

LLY

1,070.24

-1.32%↓

JNJ

223.71

+0.13%↑

ABBV

214.91

+0.85%↑

UNH

376.87

-0.39%↓

MRK

116.26

+0.55%↑

LLY

1,070.24

-1.32%↓

JNJ

223.71

+0.13%↑

ABBV

214.91

+0.85%↑

UNH

376.87

-0.39%↓

MRK

116.26

+0.55%↑

LLY

1,070.24

-1.32%↓

JNJ

223.71

+0.13%↑

ABBV

214.91

+0.85%↑

UNH

376.87

-0.39%↓

MRK

116.26

+0.55%↑

Home・Aandelen Lijst・Maravai LifeSciences Holdings Inc (Class A)

Maravai LifeSciences Holdings Inc (Class A)

Open

SectorGezondheidszorg

4.71 -0.63

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

4.6899999999999995

Max

4.87

Belangrijke statistieken
By Trading Economics
Inkomsten	36M -3.7M
Verkoop	16M 66M
EPS	0.01
Winstmarge	-5.67
Werknemers	416
EBITDA	57M 15M

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	+18.13% upside

Dividenden
By Dow Jones
Volgende Winsten	10 aug 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	225M 1.6B
Vorige openingsprijs	5.34
Vorige sluitingsprijs	4.71

Nieuwssentiment

By Acuity

50%

153 / 344 Rangschikking in Healthcare

Maravai LifeSciences Holdings Inc (Class A) Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

1 jun 2026, 23:48 UTC

Marktinformatie

Nikkei May Rise on Optimism Over AI Demand -- Market Talk

1 jun 2026, 23:38 UTC

Acquisities, Fusies, Overnames

Google Seeks $80 Billion for AI Buildout; Berkshire Will Buy $10 Billion Stake -- WSJ

1 jun 2026, 23:37 UTC

Marktinformatie

Oil Edges Higher; Trump Seeks to Quell Israel-Hezbollah Conflict -- Market Talk

1 jun 2026, 23:01 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

1 jun 2026, 23:01 UTC

Marktinformatie

Dexus Stuck in 'Too Hard' Basket -- Market Talk

1 jun 2026, 22:08 UTC

Acquisities, Fusies, Overnames

Alphabet to Issue $80 Billion of Equity for AI Buildout. Berkshire to Buy $10 Billion. -- Barrons.com

1 jun 2026, 22:01 UTC

Acquisities, Fusies, Overnames

Alphabet to Issue $80 Billion of Equity for AI Buildout. Berkshire to Buy $10 Billion. -- Barrons.com

1 jun 2026, 22:01 UTC

Acquisities, Fusies, Overnames

Google Seeks to Raise $80 Billion for AI Infrastructure -- Update

1 jun 2026, 21:55 UTC

Acquisities, Fusies, Overnames

Greg Abel's Week Is Off to Quite a Start -- WSJ

1 jun 2026, 21:53 UTC

Marktinformatie

Strong Earnings Suppress Concerns About Oil Market -- Market Talk

1 jun 2026, 21:22 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Berkshire's Abel Takes Big Swing With Back-to-Back Deals -- Market Talk

1 jun 2026, 20:50 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Tech, Media & Telecom Roundup: Market Talk

1 jun 2026, 20:50 UTC

Marktinformatie

Health Care Roundup: Market Talk

1 jun 2026, 20:50 UTC

Marktinformatie

Auto & Transport Roundup: Market Talk

1 jun 2026, 20:46 UTC

Acquisities, Fusies, Overnames

The Odds SpaceX Merges With Tesla Are Higher Than You Think -- Barrons.com

1 jun 2026, 20:22 UTC

Acquisities, Fusies, Overnames

Array Digital Infrastructure Doesn't Expect Additional Divs in 2026

1 jun 2026, 20:21 UTC

Acquisities, Fusies, Overnames

Array Digital Infrastructure Div Payable June 25 to Hldrs of Record June 11

1 jun 2026, 20:21 UTC

Acquisities, Fusies, Overnames

Array Digital Infrastructure Declares $11 Special Div

1 jun 2026, 20:20 UTC

Acquisities, Fusies, Overnames

Array Completes Sale of Select Spectrum Assets to Verizon for $1B

1 jun 2026, 19:40 UTC

Marktinformatie

Remittances to Mexico Rise for Third Straight Month -- Market Talk

1 jun 2026, 19:28 UTC

Marktinformatie

BoC Official Reiterates Need to Improve Business Investment -- Market Talk

1 jun 2026, 19:01 UTC

Marktinformatie

Oil Futures Rise On Concerns About U.S.-Iran Talks -- Market Talk

1 jun 2026, 18:58 UTC

Marktinformatie

U.S. Natural Gas Futures Snap 3-Session Winning Streak -- Market Talk

1 jun 2026, 18:54 UTC

Acquisities, Fusies, Overnames

Berkshire Stock Drops. Its Bargain-Priced Deal for Home Builder Fails to Impress Investors. -- Barrons.com

1 jun 2026, 18:33 UTC

Marktinformatie

Mexican PMIs Show Sluggish Manufacturing in May -- Market Talk

1 jun 2026, 18:32 UTC

Marktinformatie

Precious Metals Fall to Start June -- Market Talk

1 jun 2026, 18:00 UTC

Acquisities, Fusies, Overnames

Marsh McLennan Agency Completes Acquisition Of TriBridge Partners >MRSH

1 jun 2026, 17:18 UTC

Marktinformatie

Global Asset Managers Accumulate Canadian Government Debt -- Market Talk

1 jun 2026, 17:18 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

1 jun 2026, 17:10 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Salesforce Estimated to Get $225M Sales Boost From Contentful -- Market Talk

Peer Vergelijking

Prijswijziging

Maravai LifeSciences Holdings Inc (Class A) Prognose

Koersdoel

By TipRanks

18.13% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 5.67 USD 18.13%

Hoogste 6 USD

Laagste 5 USD

Gebaseerd op 5 Wall Street-analisten die 12-maands prijsdoelen bieden voor Maravai LifeSciences Holdings Inc (Class A) - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

5 ratings

Buy

Hold

Sell

Gebaseerd op 5 analisten die aandelenratings hebben gegeven aan Maravai LifeSciences Holdings Inc (Class A) - Dist in de afgelopen 3 maanden.

Sentiment

By Acuity

153 / 344 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Maravai LifeSciences Holdings Inc (Class A)

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.